Takeda Pharmaceutical Company stock kpis
Want to see TAK full AI Analyst Report?
Revenue by Segment
In Q2 FY2026, Takeda Pharmaceutical Company reported revenue by segment of ¥385.80B (GI), ¥194.00B (Rare Disease), ¥273.10B (Plasma-Derived Therapies), ¥148.80B (Oncology), ¥108.40B (Neuroscience) and ¥23.30B (Vaccines).
Analyzes income from different business units, highlighting which segments drive growth and profitability, and indicating areas of strategic focus or potential vulnerability.
Takeda's revenue from Plasma-Derived Therapies and Oncology segments shows robust growth, reflecting strategic focus and successful product launches. However, Neuroscience revenue is declining, likely impacted by the loss of exclusivity for VYVANSE, which caused a significant revenue drop. The earnings call highlights a mixed outlook with currency headwinds and impairment losses affecting profitability, yet optimism remains for H2 due to anticipated growth in launch products and strategic partnerships, particularly in oncology. Investors should watch for recovery in Neuroscience and potential upside from new pipeline advancements.
No longer reported by the company (last reported Q2 FY2026)
TAK Revenue by Segment
| Period | GI | Rare Disease | Plasma-Derived Therapies | Oncology | Neuroscience | Vaccines | Others |
|---|---|---|---|---|---|---|---|
| Q2 FY2026Sep 30, 2025 | ¥385.80B | ¥194.00B | ¥273.10B | ¥148.80B | ¥108.40B | ¥23.30B | ¥58.30B |
| Q1 FY2026Jun 30, 2025 | ¥353.50B | ¥184.10B | ¥256.60B | ¥149.10B | ¥97.50B | ¥20.20B | ¥51.90B |
| Q4 FY2025Mar 31, 2025 | ¥339.30B | ¥196.40B | ¥260.90B | ¥138.80B | ¥108.60B | ¥11.50B | ¥51.20B |
| Q3 FY2025Dec 31, 2024 | ¥317.70B | ¥173.80B | ¥248.50B | ¥132.00B | ¥109.30B | ¥5.50B | ¥66.50B |
| Q2 FY2025Sep 30, 2024 | ¥344.10B | ¥190.40B | ¥248.50B | ¥143.40B | ¥141.90B | ¥11.80B | ¥64.00B |
| Q1 FY2025Jun 30, 2024 | ¥346.70B | ¥189.20B | ¥264.20B | ¥142.90B | ¥145.50B | ¥25.60B | ¥61.90B |
| Q4 FY2024Mar 31, 2024 | ¥348.50B | ¥199.50B | ¥271.40B | ¥142.10B | ¥169.10B | ¥12.50B | ¥64.90B |
| Q3 FY2024Dec 31, 2023 | ¥280.20B | ¥164.10B | ¥229.20B | ¥116.10B | ¥152.10B | ¥20.80B | ¥88.30B |
| Q2 FY2024Sep 30, 2023 | ¥339.20B | ¥183.40B | ¥244.30B | ¥121.10B | ¥144.20B | ¥11.70B | ¥67.30B |
| Q1 FY2024Jun 30, 2023 | ¥303.30B | ¥170.10B | ¥221.00B | ¥114.70B | ¥153.70B | ¥7.30B | ¥73.10B |
| Q4 FY2023Mar 31, 2023 | ¥293.50B | ¥170.80B | ¥209.20B | ¥110.50B | ¥177.00B | ¥10.50B | ¥87.00B |
| Q3 FY2023Dec 31, 2022 | ¥237.00B | ¥169.80B | ¥0.00 | ¥93.80B | ¥160.60B | ¥0.00 | ¥118.90B |
| Q2 FY2023Sep 30, 2022 | ¥311.10B | ¥191.40B | ¥0.00 | ¥119.70B | ¥174.80B | ¥0.00 | ¥111.10B |
| Q1 FY2023Jun 30, 2022 | ¥276.00B | ¥180.60B | ¥0.00 | ¥107.80B | ¥159.90B | ¥0.00 | ¥105.90B |
| Q4 FY2022Mar 31, 2022 | ¥270.40B | ¥181.60B | ¥0.00 | ¥117.50B | ¥142.40B | ¥0.00 | ¥118.70B |
| Q3 FY2022Dec 31, 2021 | ¥210.00B | ¥148.30B | ¥0.00 | ¥109.60B | ¥119.70B | ¥0.00 | ¥142.00B |
| Q2 FY2022Sep 30, 2021 | ¥236.60B | ¥162.80B | ¥0.00 | ¥125.40B | ¥128.90B | ¥0.00 | ¥122.30B |
| Q1 FY2022Jun 30, 2021 | ¥218.60B | ¥144.60B | ¥0.00 | ¥112.30B | ¥120.30B | ¥0.00 | ¥118.20B |
| Q4 FY2021Mar 31, 2021 | ¥210.50B | ¥155.50B | ¥0.00 | ¥121.40B | ¥113.40B | ¥0.00 | ¥241.60B |
| Q3 FY2021Dec 31, 2020 | ¥189.00B | ¥145.00B | ¥0.00 | ¥98.00B | ¥102.20B | ¥0.00 | ¥128.70B |
| Q2 FY2021Sep 30, 2020 | ¥209.00B | ¥151.30B | ¥0.00 | ¥108.40B | ¥107.30B | ¥0.00 | ¥153.50B |
| Q1 FY2021Jun 30, 2020 | ¥192.90B | ¥140.40B | ¥0.00 | ¥102.10B | ¥100.90B | ¥0.00 | ¥152.00B |
| Q4 FY2020Mar 31, 2020 | ¥186.90B | ¥155.00B | ¥0.00 | ¥108.00B | ¥106.90B | ¥0.00 | ¥139.80B |

